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A B S T R A C T
Bi-allelic mutations in the glucocerebrosidase gene (GBA1) cause Gaucher's disease, the most common human
lysosomal storage disease. We previously reported a marked increase in miR-155 transcript levels and early
microglial activation in a zebraﬁsh model of Gaucher's disease (gba1−/−). miR-155 is a master regulator of
inﬂammation and has been implicated in a wide range of diﬀerent neurodegenerative disorders. The observed
miR-155 upregulation preceded the subsequent development of widespread pathology with marked neuroin-
ﬂammation, closely resembling human Gaucher's disease pathology. We now report similar increases of miR-155
expression in mammalian models of GD, conﬁrming that miR-155 upregulation is a shared feature in gluco-
cerebrosidase (GCase) deﬁciency across diﬀerent species. Using CRISPR/Cas9 mutagenesis we then generated a
miR-155 mutant zebraﬁsh line (miR-155−/−) with completely abolished miR-155 expression. Unexpectedly, loss
of miR-155 did not mitigate either the reduced lifespan or the robust inﬂammatory phenotypes of gba1−/−
mutant zebraﬁsh. Our data demonstrate that neither neuroinﬂammation nor disease progression in GCase de-
ﬁciency are dependent on miR-155 and suggest that miR-155 inhibition would not be a promising therapeutic
target in Gaucher's disease.
1. Introduction
miR-155 is a typical multifunctional miRNA which is involved in a
wide range of diﬀerent immune and inﬂammatory processes (Faraoni
et al., 2009). Inﬂammation is increasingly recognised as a key me-
chanism leading to neurodegenerative diseases with an observed up-
regulation of miR-155 in Parkinson's disease (PD), multiple sclerosis
(MS), motor neuron disease (MND), Alzheimer's disease (AD) and other
dementias (Butovsky et al., 2015; Caggiu et al. 2018; Chen et al., 2018;
Tili et al. 2018). In MND, miR-155 is strongly upregulated in the spinal
cord of both familial and sporadic MND with dysregulation of pre-
viously validated miR-155 downstream targets in the lumbar ventral
horn (Butovsky et al., 2015). Genetic ablation of miR-155 ameliorated
disease severity and prolonged survival in SOD1G93A mice, a widely
used rodent model of MND. Furthermore, treating SOD1G93A mice with
anti-miR-155 at the beginning of disease onset also improved the dis-
ease phenotype and prolonged the lifespan, suggesting that miR-155
could be a therapeutic target for human MND (Butovsky et al., 2015).
In post-mortem studies of PD patient brains, activated microglia and
increased concentrations of pro-inﬂammatory cytokines have been
identiﬁed within the substantia nigra (Boka et al., 1994; McGeer et al.,
1988). An increase in pro-inﬂammatory cytokines in both PD patient
serum and cerebrospinal ﬂuid (CSF) has been reported (Dobbs et al.,
1999; Mogi et al., 1994). Distinct cytokine proﬁles may be associated
with more aggressive progression of the disease (Williams-Gray et al.,
2016). Genetic studies of risk factors for PD and epidemiological studies
also support the role of inﬂammation in PD (Kaur et al. 2017). miR-155
is signiﬁcantly upregulated in the substantia nigra pars compacta
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(SNpc) of mice with adeno-associated-virus-mediated expression of
alpha-synuclein. This rodent model of PD demonstrated microgliosis
and a 30% loss of dopaminergic neurons. In contrast, miR-155−/− mice
transduced with alpha-synuclein showed attenuated inﬂammatory re-
sponses and near complete neuroprotection (Thome et al., 2016).
Heterozygous mutations in GBA1 are the most common risk factor
for PD (Gegg and Schapira, 2018) whilst bi-allelic GBA1 mutations
cause Gaucher's disease (GD), the most common lysosomal storage
disorder (Davidson et al., 2018). A key pathological feature of GD is the
inﬁltration and accumulation of Gaucher cells in many diﬀerent organs,
particularly the haemopoietic system (Baris et al., 2014). Gaucher cells
are inﬁltrating glycolipid-engorged macrophages and the source of in-
creased inﬂammatory markers observed in GD patients (Panicker et al.,
2014). Neuroinﬂammation is thought to be a major contributing feature
to neurodegeneration in GD, as demonstrated by the upregulation of
inﬂammatory markers, astrogliosis, and microglial activation corre-
lating with neuronal loss in two murine models of GD (Farfel-Becker
et al. 2011; Massaro et al., 2018; Vitner et al., 2012). Microglial acti-
vation is therefore a common feature in both PD and GD brains (Ginns
et al., 2014). Of note, plasma levels of monocyte-associated in-
ﬂammatory markers (including IL8, MCP-1, MIP1α, SCF, and PARC) are
increased in GBA1+/− PD patients and increased IL8 levels were also
associated with poorer cognition (Chahine et al., 2013). This suggests
that inﬂammation may be a particularly important aspect of pathogenic
mechanism in GBA-linked PD.
We recently described a gba1 mutant zebraﬁsh line (gba−/−) gen-
erated by TALEN mutagenesis which faithfully modelled key aspects of
human GD, including Gaucher cell accumulation, neurodegeneration
and marked elevation of GD biomarkers. We observed early activation
of immune/inﬂammatory mechanisms with microglial activation and
increased miR-155 transcription levels at 4 or 5 days post fertilisation
(dpf) respectively. Of note, both the early microglial activation and the
accompanying miR-155 activation dramatically preceded the onset of a
change in phenotype which only occurred at around 8–10weeks with
resulting lethality around 12weeks of age. Compared to the larval
stages, we observed a striking inﬂammatory phenotype at 12 weeks,
with a further increase of miR-155 levels and marked microglial ac-
cumulation (Keatinge et al., 2015).
The aim of this study was therefore to investigate whether miR-155
upregulation may be a universal feature of GCase deﬁciency in mam-
malian models systems of GD and to determine whether miR-155
ablation may have a neuroprotective eﬀect in gba1 deﬁciency.
2. Methods
2.1. Zebraﬁsh husbandry
All larval and adult zebraﬁsh were housed at the University of
Sheﬃeld; experimental procedures being in accordance UK Home
Oﬃce Animals (Scientiﬁc Procedures) Act 1986 (Project licence PPL
70/8437, held by Professor Oliver Bandmann). Adult zebraﬁsh were
housed at a density of 40 per tank, on a cycle of 14 h of light, 10 h of
dark. Adults and embryos were kept at constant temperature of 28 °C.
The gba1−/− and pink1−/− mutant lines were previously described
in (Keatinge et al., 2015) and (Flinn et al., 2013) respectively. The miR-
155 mutant line was generated by the CRISPR/Cas9 method, using a




guide RNAs (gRNAs) were generated from a DNA ultramer template
(IDT) and transcribed using a T7 MEGAshortscript™ kit (Invitrogen).
gRNAs were then co-injected into one-cell stage zebraﬁsh embryos with
Cas9 protein (NEB). F0 injected embryos were raised to 3months then
crossed to wild type (WT) to identify founders. The progeny of selected
F0 founders were then outcrossed to generate the F1 generation where
appropriate mutant alleles were identiﬁed and selected for further
study. The line was genotyped using primers F 5’-TATGACGTCCACAT
GCATGC and R 5’-GATGTTCAGACGGTTCGCTC.
miR-155+/− were crossed to gba1+/− to generate double hetero-
zygous individuals. These were subsequently in-crossed to generate
double mutants. At each in-cross larvae were genotyped at 3dpf by
larval tail biopsy as previously described (Wilkinson et al., 2013) and
each genotype raised in genotype-speciﬁc tanks at a density of 10–15
ﬁsh per tank. All individuals were re-genotyped at 10 weeks post-fer-
tilisation.
2.2. Gene expression analyses
RNA was extracted from zebraﬁsh adult brains (12wpf), cortex of
21 day old Gbaﬂox/ﬂox; nestin-Cre and Gbaﬂox/WT; nestin-Cre mice, or
BV2 microglial cells at speciﬁc time points using TRIzol® (Life
Fig. 1. miR-155 and associated inﬂammatory mar-
kers are upregulated in diﬀerent models of GCase
deﬁciency.
(A) miR-155 expression is upregulated in the cortex
of the Gbaﬂox/ﬂox; Nestin-Cre neuropathic Gaucher
disease mouse model (n=6, p= .0004, one-tailed t-
test) and (B) in cultured murine microglia treated
with the GCase inhibitor CBE (n=3, p= .031, one-
tailed t-test). (C) Expression of miR-155 downstream
targets tnfa, tnfb, cxcl8-l1 and cxcl8-l2 (zebraﬁsh or-
thologues of human TNFa and IL-8) in 12 wpf zeb-
raﬁsh brain (n=3, two-way ANOVA). * p < .05, **
p < .01, *** p < .001. Error bars= SD.
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Technologies™). cDNA was synthesised using a Verso™ reverse tran-
scription kit (Thermo Fisher Scientiﬁc). Gene expression was de-
termined using Brilliant II SYBR® Green QPCR Master Mix (Agilent
Technologies) on a Stratagene MxPro 3000P (Stratagene) qPCR ma-
chine. For all experiments, ef1α was used as a reference gene.
For miRNA qPCR analysis, RNA was extracted as above. For zeb-
raﬁsh and mouse brain RNA the RNA concentration was accurately
quantiﬁed using the QuantiFluor™ RNA system (Promega) and the
Qubit® ﬂuorometer (Life Technologies). 100 ng of total RNA was re-
verse-transcribed and subsequently qPCR was performed using TaqMan
Fig. 2. Generation and validation of a miR-155 knockout line.
CRISPR/Cas9 technology was used to generate a miR-155 knockout line. (A) This schematic shows the miR-155 gene of wild type (WT) mir-155 and the mutation
generated by CRISPR/Cas9 mutagenesis. Brieﬂy, in the mutant the whole mir-155 exon is duplicated (1000 bp duplicated region); in the ﬁrst copy of mir-155 there is
a 55 bp deletion, and in the second copy there is a 253 bp insertion and 5 bp deletion. Both mutations disrupt the mature miR-155 sequence. (B) PCRs with
genotyping and whole region primers conﬁrm this complex mutation. In WT, only one amplicon of 148 bp, corresponding to the mir-155 exon, is generated using the
genotyping primers (blue). In homozygous mutants (HOM), two amplicons are generated, one for each mir-155 exon. The amplicon spanning ﬁrst exon generates a
93 bp product reﬂecting the 55 bp deletion. The amplicon spanning the second exon generates a 396 bp product reﬂecting the 253 bp insertion and 5 bp deletion. The
whole region primers (green) generate an amplicon of 1419 bp in WT and an amplicon of approximately 2400 bp in the HOMs reﬂecting the 1000 bp insertion. The
location of the PCR primers used to generate these products are shown in (A). (C) Schematic miRNA processing pathway, illustrating how the miR-155 mutation is
predicted to result in abolished production of mature miR-155. (D) The predicted complete loss of mature miR-155 was validated by qPCR for miR-155 transcripts
with miR-155 being undetectable in miR-155−/− (n=3, p= .0044, one-tailed t-test). ** p < .01. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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miRNA assays to quantify miR-155 levels. For mouse BV2 microglial
cells miRNA was extracted from cells using PureLink miRNA isolation
kit (ThermoFisher) and then converted to cDNA using TaqMan miRNA
RT Kit (ThermoFisher). TaqMan miRNA assays were used to quantify
miR-155 levels, and were normalised against U6 RNA (TaqMan,
ThermoFisher).
All primer sequences listed in supplementary information.
2.3. Microglial culture and CBE treatment
Mouse BV2 microglial cells were grown in DMEM (4.5 g/L glucose)
supplemented with 10% (v/v) fetal calf serum treated with 100 μM CBE
for 10 days, with the media changed every 3 days. miR-155 expression
was then measured as stated above.
2.4. IHC to assess microglial invasion of zebraﬁsh brain
Sample preparation for microglial IHC to investigate microglial
activation in zebraﬁsh brains was carried out as reported previously
(Bai et al., 2014). Zebraﬁsh were perfused and brains post-ﬁxed in 4%
PFA, followed by cryoprotection in PBS-sucrose. 14 μm-thick cryosec-
tions were mounted on glass slides, post-ﬁxed, treated with 3% H2O2 in
PBS for 5min, then PBS-T (0.3% Triton-X) for 1 h, blocked with 10%
goat serum in PBS for 2 h and then incubated overnight at 4 °C with
primary antibody (7.4.C4, puriﬁed from hybridoma clone, #92092321,
HPA Culture Collections, UK), diluted 1:20 in PBS with 1% goat serum.
Primary antibody was detected using a biotinylated anti-mouse anti-
body (Vector Laboratories, Burlingame, CA, USA) followed by incuba-
tion with avidin-biotin-peroxidase complexes and staining using DAB
(Vector Laboratories). Images were acquired using an Olympus BX51
compound light microscope. Microglia counts in multiple ﬁelds from 3
to 4 sections for 4 animals per group were made by an observer blinded
to genotype.
2.5. Statistical tests and analysis
Graphpad prism V7 software (Graphpad) was used for statistical
analysis and all errors bars shown denote standard deviation. All ex-
periments were performed in biological triplicate unless otherwise
stated. All data were analysed with either one-tailed t-test or two-way
ANOVA with Tukey's post-tests.
3. Results
3.1. GCase deﬁciency leads to robust increase of miR-155 and downstream
inﬂammatory markers in vitro and in vivo
To determine whether miR-155 was also upregulated in mammalian
models of GCase deﬁciency, we assessed miR-155 expression in the
brain of Gbaﬂox/ﬂox; Nestin-Cre mice; a model of neuronal GD (Vitner
et al., 2012). In this model, miR-155 levels were 6-fold increased
(Fig. 1A; n=6, p= .0004, one-tailed t-test). To complement this data,
we also analysed miR-155 expression in mouse BV2 microglial cells
treated with the GCase inhibitor conduritol-B-epoxide (CBE) for
10 days. CBE treatment inhibited GCase activity by 90.6% (Control,
214.0 ± 5.3 nmol/h/mg protein; CBE, 20.1 ± 3.2 nmol/h/mg pro-
tein) and resulted in a 1.5-fold increase in miR-155 relative to untreated
controls (Fig. 1B; n=3, p= .031, one-tailed t-test). These results
conﬁrm that miR-155 upregulation is not limited to gba1−/− zebraﬁsh
but can also be observed in mammalian models of GCase deﬁciency. To
determine whether miR-155 levels were elevated in other zebraﬁsh
models of neurodegeneration, we analysed miR-155 levels in the brains
of adult pink1 deﬁcient zebraﬁsh (Flinn et al., 2013). No increase in
miR-155 was detected (data not shown).
To conﬁrm a biological eﬀect of increased miR-155 levels, we next
determined the expression of its downstream target genes tnfa/tnfb
(orthologous to human TNFα) and cxcl8-l1/cxcl8-l2 (orthologous to
human IL8) in gba1−/− zebraﬁsh brains (Lippai et al. 2013; Min et al.,
2014; Pathak et al. 2015). Both IL8 orthologues (cxcl8-l1/cxcl8-l2) and
tnfb were 15–20 fold upregulated in brain tissue from gba1−/− zebra-
ﬁsh at 12 wpf (Fig. 1C; n=3, p < .05, two-way ANOVA). TNFα was
also previously shown to be highly upregulated in brain tissue of
Gbaﬂox/ﬂox; Nestin-Cre mice (Vitner et al., 2012).
3.2. Generation of a miR-155 knock out line using CRISPR/Cas9
Having established that miR-155 upregulation is conserved in
mammalian genetic and chemically-induced models of GCase deﬁ-
ciency, we next sought to determine whether miR-155 inactivation
could be neuroprotective in the context of GCase deﬁciency. We used
CRIPSR/Cas9 technology to generate a stable mutant miR-155 zebraﬁsh
line. A mutant with a complex genetic mutation was identiﬁed. There is
a tandem duplication of the mir-155 gene, one copy carries a 55 bp
deletion and the other carries a large insertion (253 bp) and small 5 bp
deletion (Fig. 2A-B). miRNAs genes are transcribed by RNA polymerase
II, the resultant transcript, usually around 80 nucleotides, adopts a
hairpin loop secondary structure called the pri-miRNA. The pri-miRNA
is exported to the cytoplasm and cleaved to produce the mature miRNA
(Fig. 2C). The mutation generated in our mutant miR-155 zebraﬁsh line
signiﬁcantly disrupts the sequence of the miRNA gene; we hypothesised
that this would prevent the correct folding of the pri-miRNA and sub-
sequent processing of the mature miRNA. Furthermore, the mature
miRNA sequence itself is disrupted by the mutation. In the ﬁrst miRNA
gene resulting from the duplication only 5 bp of the mature miRNA
sequence remains; in the second, a large insertion is present in the
middle of the mature miRNA sequence. To conﬁrm the deleterious ef-
fect of the complex mir-155 mutation, a TaqMan™MicroRNA Assay was
applied. This assay uses a looped-primer RT-PCR to speciﬁcally re-
cognise the mature miRNA sequence. As predicted, this experiment
conﬁrmed the complete absence of mature miR-155 in the brain tissue
Fig. 3. Genetic ablation of miR-155 does not increase survival or ameliorate
inﬂammatory phenotype in gba1 mutants.
(A) Lifespan of single (gba−/−) and double mutants (gba1−/−;miR-155−/−).
The median survival was 99.5dpf in gba1−/− and 103dpf in gba1−/−;miR-
155−/− (n=11–13 per group). (B) Loss of miR-155 does not aﬀect expression
of inﬂammatory markers as assessed by qPCR (n=4, two-way ANOVA) *
p < .05, ** p < .01, ***=p < .001. Error bars= SD.
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of miR-155−/− zebraﬁsh (Fig. 2D, n=3, p= .0044, one-tailed t-test).
3.3. Genetic ablation of miR-155 does not increase survival or alter
inﬂammatory phenotypes of gba1−/− zebraﬁsh
To assess the eﬀects of loss of miR-155 in gba1−/− zebraﬁsh, miR-
155+/− animals were crossed with gba1+/− to generate gba1+/−; miR-
155+/− zebraﬁsh; these were subsequently in-crossed to generate
double homozygous mutants (gba1−/−;miR-155−/−). Until 12 weeks
post fertilisation, gba1−/− zebraﬁsh are visibly indistinguishable from
their wild-type siblings. Around this age they develop a rapidly pro-
gressive movement phenotype and become emaciated. This is caused by
extensive neurodegeneration accompanied by a strong
neuroinﬂammatory phenotype (Keatinge et al., 2015). Unexpectedly,
genetic ablation of miR-155 did not modulate the lifespan (Fig. 3A) of
gba−/− zebraﬁsh (median survival 99.5dpf in gba1−/− and 103dpf in
gba1−/−;miR-155−/−, n=13) or the emergence of abnormal motor
function (data not shown).
We next determined whether this absence of rescue in this model
was attributable to lack of involvement of neuroinﬂammation in the
phenotype versus miR-155 being unnecessary for neuroinﬂammation in
this model. We had previously demonstrated marked microglial accu-
mulation in the optic tectum and cerebellum in end stage gba1−/−
zebraﬁsh (Keatinge et al., 2015). Genetic ablation of miR-155 did not
ameliorate upregulation of tnfb or cxcl8-l1/l2 (Fig. 3B), or CNS micro-
glial accumulation in gba1−/− brains (Fig. 4). Unexpectedly, in the
Fig. 4. miR-155 ablation does not reduce microglial accumulation in gba1−/− zebraﬁsh.
(A-B) Brains from WT, gba1−/−, miR-155−/− and gba1−/−;miR-155−/− zebraﬁsh were labelled using a microglial antibody marker 7.4.C4. Sections from com-
parable parts of the (A) optic tectum and (B) cerebellum are shown for each genotype, oriented rostral to left; scale bar for all images is shown in bottom left panel.
(C-D) Microglial abundance was analysed for each genotype (2 sections each from 4 brains for each genotype). Immunoreactive microglia were quantiﬁed within
each brain region of interest (C) optic tectum, (D) cerebellum and expressed as the density of microglia per square mm of brain region imaged (n=8, two-way
ANOVA). ** p < .01, **** p < .0001. Error bars= SD.
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optic tectum, gba1−/−;miR-155−/− zebraﬁsh had a further 40% in-
crease in microglial abundance compared to gba1−/− (Fig. 4C; 218
microglia/mm2 to 150 microglia/mm2, n=8, p < .01, two-way
ANOVA with Tukey's post-tests).
4. Discussion and conclusions
There is growing interest in the role of epigenetic mechanisms in
neurodegeneration but observations are frequently limited to model
systems of one species and can be of uncertain functional relevance.
The mature sequence of miR-155 is 100% conserved between zeb-
raﬁsh and humans, similarly, the predicted binding sites in the 3’UTRs
of many of the known targets of miR-155 are also conserved between
zebraﬁsh and humans. It is thought that miR-155 exerts its pro-in-
ﬂammatory eﬀects through targets such as SOCS1 which have key
function as negative regulators on cytokines (Wang et al. 2018; Yao
et al., 2012). Suppression of SOCS1, and other similar targets, by miR-
155 leads to an elevation of cytokine levels and pro-inﬂammatory ef-
fects (Testa et al., 2017). The miRNA target prediction software Tar-
getScan predicts a miR-155 binding site in position 15–21 in the 3’UTR
of zebraﬁsh socs1.
We showed that miR-155 was upregulated in three vertebrate
models of GCase deﬁciency: gba1−/− zebraﬁsh, Gbaﬂox/ﬂox; Nestin-Cre
mice, and mouse BV2 microglia treated with CBE, a GCase inhibitor. We
also showed that the orthologues of TNFα and IL-8, inﬂammatory
markers which are regulated by direct targets of miR-155 (Lippai et al.
2013; Min et al., 2014; Pathak et al. 2015), are also highly upregulated
in the brains of gba1 deﬁcient zebraﬁsh. IL-8 was shown to be upre-
gulated in PD patients with GBA mutations (Chahine et al., 2013) and
TNFα is upregulated in GD patient serum and in the brain of Gbaﬂox/ﬂox;
Nestin-Cre mice (Barak et al., 1999; Vitner et al., 2012). These ﬁndings
demonstrate that the pathogenic processes leading to miR-155 upre-
gulation and inﬂammation is present in both mouse and zebraﬁsh
models of GCase deﬁciency.
We used CRISPR/Cas9 to generate a miR-155 mutant line and de-
monstrated with the Taqman™miRNA assay that mature miR-155 is not
produced in this miR-155 mutant line. In miR-155 mutants, the in-
ﬂammatory marker cxcl8-l1, a classical miR-155 downstream target,
was reduced 50% compared to WT zebraﬁsh, however this did not
reach signiﬁcance. Unexpectedly, loss of miR-155 did not have an eﬀect
on the survival or inﬂammatory phenotypes of gba1 mutant zebraﬁsh.
This suggests that, at least in zebraﬁsh, miR-155 does not play a cau-
sative role for neuroinﬂammation in GCase deﬁciency and suggests
redundancy of inﬂammatory pathways. Loss of miR-155 had no eﬀect
on the upregulation of tnfb or cxcx8-l1/l2 in gba1−/− zebraﬁsh. This
may be because of alternate pathways, which are not dependant on
miR-155 targets, leading to their upregulation and the loss of repression
of miR-155 targets may not be strong enough to overcome this eﬀect.
We cannot comment whether miR-155 is able to regulate socs1 in
zebraﬁsh; luciferase assays or western blots are required to determine
the eﬀect of miRNAs on their direct targets as they exert their eﬀects
post-transcriptionally. It is possible that although the mature miR-155
sequence is conserved in zebraﬁsh the binding sites in key anti-in-
ﬂammatory targets may not be as well conserved and therefore miR-
155 may exert a weaker, or have no eﬀect on these targets.
Although zebraﬁsh are a powerful model for genetic studies and
70% of human genes have at least one clear orthologue, many genes
have two orthologues due to a large genome duplication event in the
zebraﬁsh genome (Howe et al., 2013). In many cases it is not clear
which gene copy is functional or, where both are, which is most closely
related to its human counterpart. Our study provides evidence that the
two zebraﬁsh orthologues of TNFα, tnfa and tnfb, function diﬀerently.
We showed that in brains of 3-month-old gba1 mutant zebraﬁsh tnfb
was upregulated 8-fold while tnfa was unchanged, this highlights the
importance of investigating both orthologues where they are present.
Our observation of marked pro-inﬂammatory changes in gba1−/
−;miR-155−/− zebraﬁsh suggests redundancy of pro-inﬂammatory
pathways in GCase deﬁciency, at least in zebraﬁsh this contrasts with a
possible role of miR-155 in other forms of neurodegeneration. The
observed rescue eﬀect of miR-155 inactivation in mouse model systems
of MND, PD and EAE may either reﬂect a more speciﬁc involvement of
miR-155 in these conditions or reduced redundancy in mammalian
model systems.
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